Compare Aurobindo Pharma with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PROCTER & GAMBLE HEALTH AUROBINDO PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 14.3 55.4 25.8% View Chart
P/BV x 3.1 5.0 61.9% View Chart
Dividend Yield % 0.4 9.5 4.3%  

Financials

 AUROBINDO PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
AUROBINDO PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs8093,549 22.8%   
Low Rs5041,301 38.7%   
Sales per share (Unadj.) Rs281.1511.4 55.0%  
Earnings per share (Unadj.) Rs41.461.3 67.5%  
Cash flow per share (Unadj.) Rs50.974.0 68.7%  
Dividends per share (Unadj.) Rs2.50440.00 0.6%  
Dividend yield (eoy) %0.418.1 2.1%  
Book value per share (Unadj.) Rs199.4927.8 21.5%  
Shares outstanding (eoy) m585.8816.60 3,529.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.34.7 49.3%   
Avg P/E ratio x15.939.6 40.1%  
P/CF ratio (eoy) x12.932.8 39.4%  
Price / Book Value ratio x3.32.6 126.0%  
Dividend payout %6.0717.9 0.8%   
Avg Mkt Cap Rs m384,63040,257 955.4%   
No. of employees `00017.31.1 1,528.4%   
Total wages/salary Rs m21,3081,313 1,623.2%   
Avg. sales/employee Rs Th9,500.77,486.7 126.9%   
Avg. wages/employee Rs Th1,229.41,157.6 106.2%   
Avg. net profit/employee Rs Th1,397.9897.2 155.8%   
INCOME DATA
Net Sales Rs m164,6668,490 1,939.5%  
Other income Rs m1,020244 418.1%   
Total revenues Rs m165,6868,734 1,897.1%   
Gross profit Rs m37,7181,482 2,545.7%  
Depreciation Rs m5,580211 2,641.9%   
Interest Rs m7770-   
Profit before tax Rs m32,3801,514 2,138.3%   
Minority Interest Rs m310-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m8,183563 1,454.7%   
Profit after tax Rs m24,2291,017 2,381.5%  
Gross profit margin %22.917.5 131.3%  
Effective tax rate %25.337.1 68.0%   
Net profit margin %14.712.0 122.8%  
BALANCE SHEET DATA
Current assets Rs m121,87815,343 794.4%   
Current liabilities Rs m86,8061,960 4,428.4%   
Net working cap to sales %21.3157.6 13.5%  
Current ratio x1.47.8 17.9%  
Inventory Days Days13049 266.5%  
Debtors Days Days6828 240.3%  
Net fixed assets Rs m81,0371,209 6,701.2%   
Share capital Rs m586166 353.0%   
"Free" reserves Rs m116,21815,235 762.8%   
Net worth Rs m116,80415,401 758.4%   
Long term debt Rs m4,5120-   
Total assets Rs m211,05217,595 1,199.5%  
Interest coverage x42.7NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.80.5 161.7%   
Return on assets %11.85.8 204.9%  
Return on equity %20.76.6 314.0%  
Return on capital %27.410.3 266.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,7271,636 4,933.5%   
Fx outflow Rs m34,7004,368 794.4%   
Net fx Rs m46,027-2,732 -1,684.9%   
CASH FLOW
From Operations Rs m19,548-1,304 -1,499.3%  
From Investments Rs m-19,57012,697 -154.1%  
From Financial Activity Rs m8,642-301 -2,875.7%  
Net Cashflow Rs m8,92211,093 80.4%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 8.0 18.2 43.7%  
FIIs % 27.7 1.0 2,770.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 29.1 35.1%  
Shareholders   69,601 28,591 243.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SANOFI INDIA  TORRENT PHARMA  PLETHICO PHARMA  CIPLA  ABBOTT INDIA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - GLENMARK PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS